Ocriplasmin
Novartis eye drug succeeds in Phase III trial
August 16, 2012Sales and Marketing FDA, Novartis, Ocriplasmin, Roche, VMA
Novartis has posted positive results for its investigational eye drug ocriplasmin. The Phase III study found that ocriplasmin significantly resolved …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
